Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients With Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC)

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients With Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Docetaxel; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms MATTERHORN
  • Sponsors AstraZeneca; AstraZeneca AB

Most Recent Events

  • 28 Jul 2025 According to an AstraZeneca media release, trial will continue to follow OS, which will be formally assessed at the final analysis.
  • 28 Jul 2025 According to an AstraZeneca media release, the trial enrolled participants in 176 centers in 20 countries, including in the US, Canada, Europe, South America and Asia.
  • 28 Jul 2025 According to an AstraZeneca media release, based on results from this trial the sBLA for imnfinzi has been accepted and granted priority review and breakthrough therapy designation by US FDA. The presciption drug user fee Act date anticipated during the fourth quarter of 2025. Regulatory applications are currently under review in the EU, Japan and several other countries based on the MATTERHORN results.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top